# Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection

> **NCT04978051** · PHASE2 · COMPLETED · sponsor: **Sebastian Videla** · enrollment: 73 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Firazyr
- **OTHER:** SoC

## Key facts

- **NCT ID:** NCT04978051
- **Lead sponsor:** Sebastian Videla
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-03-17
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978051, "Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04978051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*